Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
The hospital has recently launched Radionuclide therapy
Subscribe To Our Newsletter & Stay Updated
